Christopher Manganaris, MD
Pulmonary Disease · Guntersville, ALNPI 1447394648
Payments from drug & device makers
Across 366 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Grifols USA, LLC$782
- Inspire Medical Systems, Inc.$723
- AstraZeneca$661
- Boehringer Ingelheim$544
- Axsome Therapeutics, Inc.$540
- plus $2K from 15 others
What the payments were for
- Food & beverage$7,56797%
- Education$1953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 128 | $2,321 |
| Grifols USA, LLC | 35 | $782 |
| Inspire Medical Systems, Inc. | 9 | $723 |
| AstraZeneca | 33 | $661 |
| Boehringer Ingelheim | 28 | $544 |
| Axsome Therapeutics, Inc. | 34 | $540 |
| Mylan Specialty L.p. | 25 | $515 |
| Regeneron Healthcare Solutions, Inc. | 12 | $380 |
| Sanofi | 13 | $308 |
| Harmony Biosciences LLC | 7 | $244 |
| Amgen | 9 | $191 |
| Sunovion Pharmaceuticals Inc. | 14 | $174 |
| Insmed, Inc. | 7 | $128 |
| Jazz Pharmaceuticals Inc. | 2 | $81 |
| Inogen, Inc. | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Lilly USA, LLC | 1 | $24 |
| Viatris Specialty LLC | 1 | $24 |
| Advanced Respiratory, Inc | 1 | $21 |
| Novo Nordisk | 1 | $15 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,761 in reported general payments places this provider in the 65th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 44 | $572,426 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 47 | $339,712 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 402 | $300,363 |
| Breo ElliptaFluticasone/Vilanterol | 172 | $78,177 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 92 | $62,475 |
| Spiriva RespimatTiotropium Bromide | 90 | $46,238 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 53 | $24,754 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $15,560 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $14,637 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $11,030 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $10,915 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 426 | $10,083 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $7,125 |
| DuleraMometasone/Formoterol | 20 | $7,075 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $544 | $648,861180 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,321 | $414,210648 claims |
| Grifols USA, LLCProlastin C | $782 | $339,71247 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $661 | $79,006140 claims |
| MerckDulera | $15 | $7,07520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Guntersville
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
- Bryan GarciaBirmingham$606K
- A RidgewaySheffield$434K
- Darryle BullardCullman$380K
- Marvin SextonDothan$346K
- Veena AntonyBirmingham$327K
- William SaliskiMontgomery$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.